Balyasny Asset Management LLC Syndax Pharmaceuticals Inc Transaction History
Balyasny Asset Management LLC
- $57.8 Billion
- Q1 2025
A detailed history of Balyasny Asset Management LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Balyasny Asset Management LLC holds 1,817,009 shares of SNDX stock, worth $16 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,817,009
Previous 69,586
2511.17%
Holding current value
$16 Million
Previous $919,000
2329.92%
% of portfolio
0.04%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding SNDX
# of Institutions
240Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$75.1 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$69.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$43 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$37.2 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$35.4 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $499M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...